Stocks›Healthcare›MRK

MRK

Merck & Co., Inc.

NYSEResearch view

Merck & Co., Inc. operates in the Pharmaceutical Preparations industry.

HealthcarePharmaceutical PreparationsMega-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

Not enough closes to draw the last 90 days.

2 stories have a settled receipt so far (2 on the Wire). The record starts speaking at three.

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Oct 30, 2025 and Oct 31, 2024, before the open.

Last report

Aug 4, 2026+0.18%

before the open

Last 4, next close

median 0.98% either way

up 2 of 4

Every report since 2022 →Earnings calendar →

DateEventSourceNext close

Aug 25Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?Yahoo FinanceYahoo Finance+3.84%
Aug 21Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial SuccessZeroHedgeZeroHedge+2.39%
Aug 4Earnings release, before the open · 8-KSEC EDGARSEC EDGAR ↗+0.18%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

What happened · big days

20 big days in a year, and what we hold on each

A big day is a close more than 3.10% from the one before, three times MRK’s median day (1.03%). On 9 of the 20, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±3.10%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayMRKWhat we hold that dayGroup (median of 4) · each

1 Nov 3, 2025−4.06%
Before our storiesgroup −0.6%, did not move with it
1Nov 3, 2025−4.06%
Before our stories
−0.6% did not move with itABBV −2.8 · JNJ −1.4 · ABT +0.2 · LLY +3.9
2 Nov 11, 2025+4.84%
Before our storiesgroup +2.6%, moved with MRK
2Nov 11, 2025+4.84%
Before our stories
+2.6% moved with MRKABBV +3.0 · JNJ +2.9 · LLY +2.3 · ABT +0.9
3 Nov 18, 2025+3.84%
Before our storiesgroup +0.1%, did not move with it
3Nov 18, 2025+3.84%
Before our stories
+0.1% did not move with itLLY +0.8 · JNJ +0.2 · ABT −0.0 · ABBV −0.1
4 Nov 25, 2025+5.24%
Before our storiesgroup +0.8%, did not move with it
4Nov 25, 2025+5.24%
Before our stories
+0.8% did not move with itLLY +3.7 · ABBV +1.0 · ABT +0.7 · JNJ +0.3
5 Dec 22, 2025+3.59%
Before our storiesgroup +0.5%, did not move with it
5Dec 22, 2025+3.59%
Before our stories
+0.5% did not move with itABBV +0.5 · LLY +0.5 · JNJ +0.5 · ABT −0.2
6 Feb 9, 2026−3.51%
Before our storiesgroup −0.3%, did not move with it
6Feb 9, 2026−3.51%
Before our stories
−0.3% did not move with itLLY −1.3 · JNJ −0.6 · ABBV −0.1 · ABT +0.2
7 Feb 27, 2026+3.79%
Before our storiesgroup +2.5%, moved with MRK
7Feb 27, 2026+3.79%
Before our stories
+2.5% moved with MRKABBV +3.3 · LLY +2.9 · JNJ +2.0 · ABT +0.1
8 Mar 5, 2026−3.50%
Before our storiesgroup −1.9%, moved with MRK
8Mar 5, 2026−3.50%
Before our stories
−1.9% moved with MRKJNJ −2.3 · LLY −2.0 · ABT −1.8 · ABBV −1.6
9 Apr 8, 2026+3.27%
Before our storiesgroup +2.0%, moved with MRK
9Apr 8, 2026+3.27%
Before our stories
+2.0% moved with MRKABBV +2.5 · LLY +2.4 · ABT +1.7 · JNJ +1.2
10 Apr 17, 2026+3.13%
Before our storiesgroup +0.6%, did not move with it
10Apr 17, 2026+3.13%
Before our stories
+0.6% did not move with itLLY +2.5 · ABT +1.4 · JNJ −0.1 · ABBV −0.3
11 Apr 21, 2026−3.88%
Before our storiesgroup −1.9%, did not move with it
11Apr 21, 2026−3.88%
Before our stories
−1.9% did not move with itABT −3.4 · JNJ −2.0 · LLY −1.8 · ABBV +0.7
12 May 22, 2026+5.64%
Before our storiesgroup +0.8%, did not move with it
12May 22, 2026+5.64%
Before our stories
+0.8% did not move with itLLY +2.2 · JNJ +1.1 · ABBV +0.6 · ABT −0.4
13 Jun 4, 2026+4.85%
Before our storiesgroup +4.0%, moved with MRK
13Jun 4, 2026+4.85%
Before our stories
+4.0% moved with MRKABT +4.4 · LLY +4.3 · ABBV +3.6 · JNJ +2.2
14 Jun 15, 2026−3.49%
Nothing on MRKgroup −1.2%, did not move with it
14Jun 15, 2026−3.49%
Nothing on MRKNo MRK story, brief or results filing in our record that day
−1.2% did not move with itABBV −2.7 · JNJ −2.2 · LLY −0.3 · ABT +0.6
15 Jun 23, 2026+3.57%
Nothing on MRKgroup +2.6%, moved with MRK
15Jun 23, 2026+3.57%
Nothing on MRKNo MRK story, brief or results filing in our record that day
+2.6% moved with MRKJNJ +3.4 · ABT +3.1 · ABBV +2.1 · LLY +0.5
16 Jun 25, 2026+4.02%
Nothing on MRKgroup +2.3%, moved with MRK
16Jun 25, 2026+4.02%
Nothing on MRKNo MRK story, brief or results filing in our record that day
+2.3% moved with MRKABBV +3.5 · ABT +3.0 · JNJ +1.6 · LLY +0.9
17 Jul 2, 2026+3.34%
Nothing on MRKgroup +3.5%, moved with MRK
17Jul 2, 2026+3.34%
Nothing on MRKNo MRK story, brief or results filing in our record that day
+3.5% moved with MRKABBV +4.0 · JNJ +3.6 · ABT +3.5 · LLY +1.9
18 Jul 16, 2026+3.25%
Nothing on MRKgroup +2.7%, moved with MRK
18Jul 16, 2026+3.25%
Nothing on MRKNo MRK story, brief or results filing in our record that day
+2.7% moved with MRKABT +10.7 · ABBV +4.2 · JNJ +1.2 · LLY +1.1
19 Aug 19, 2026+12.60%
Nothing on MRKgroup +2.1%, did not move with it
19Aug 19, 2026+12.60%
Nothing on MRKNo MRK story, brief or results filing in our record that day
+2.1% did not move with itLLY +4.5 · ABBV +2.7 · ABT +1.6 · JNJ +0.8
20 Aug 25, 2026+3.84%
1 storygroup −0.2%, did not move with it
20Aug 25, 2026+3.84%
1 story “Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?” · Yahoo Finance
−0.2% did not move with itABBV +0.5 · JNJ +0.0 · ABT −0.5 · LLY −1.1

A story on the same day is not a cause, and a group move is not proof either. Group: the median of LLY, JNJ, ABBV and ABT that day, the largest companies in MRK’s SEC industry; “moved with MRK” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). MRK reports before the open, so day 1 is that day’s close. 3 of 4 times, day 6 ended on the same side as day 1.

Reported Oct 30, 2025

day 1−0.35%day 6−0.92%

Reported Feb 3, 2026

day 1+2.18%day 6+3.33%

Reported Apr 30, 2026

day 1−1.60%day 6+1.22%

Reported Aug 4, 2026

day 1+0.18%day 6+2.07%

Next report: expected late October to early NovemberEstimated from the dates of its last four results filings. Not announced. Since the Aug 4 report: +12.94%. Four reports is a small sample.

Every report since 2022 →

Each line is MRK’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

The numbers · FY2025, filed

SEC EDGAR

Market cap$356.0B

Revenue$65.0B+1.30%

Net income$18.3B

EPS, diluted$7.28+8.00%

Return on equity34.7%

Debt / equity0.94

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$356.0B

Enterprise Value$390.7B

Income$18.3B

Sales$65.0B

Book/sh$21.35

Cash/sh$5.95

Dividend TTM$3.28

Payout45%

Employees—

IPO—

Quick Ratio1.30

Current Ratio1.54

Debt/Eq0.94

EPS (ttm)$7.28

EPS this Y8.0%

EPS past 3/5Y8.4%

Sales past 3/5Y3.1%

EPS Y/Y TTM8.0%

Sales Y/Y TTM1.3%

Shs Outstand2.47B

ROA13.3%

ROE34.7%

ROIC—

Gross Margin—

Oper. Margin—

Profit Margin28.1%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$48.7B

FY21

$59.3B

FY22

$60.1B

FY23

$64.2B

FY24

$65.0B

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$48.7B	$59.3B	$60.1B	$64.2B	$65.0B
Gross Profit	—	—	—	—	—
Operating Income	—	—	—	—	—
Net Income	$12.3B	$14.5B	$365.0M	$17.1B	$18.3B
Diluted EPS	$5.14	$5.71	$0.14	$6.74	$7.28
Operating Cash Flow	$13.1B	$19.1B	$13.0B	$21.5B	$16.5B
Free Cash Flow	$8.7B	$14.7B	$9.1B	$18.1B	$12.4B

Same industry

MRK against four drug peers, a year at 100

MRK is up 61.8% in a year. All four did less: Eli Lilly (+36.1%), Johnson & Johnson (+35.7%), AbbVie (+12.4%) and Abbott (−27.6%). Weekly closes, Oct 3, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

MRK +61.8%. Eli Lilly +36.1%, Johnson & Johnson +35.7%, AbbVie +12.4%, Abbott −27.6%. Weekly closes, Oct 3, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in MRK’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

Same industry

In the screener →

LLY$1.08T JNJ$617.0B ABBV$464.4B ABT$168.7B PFE$158.5B VRTX$127.9B BMY$124.9B REGN$79.8B

Build basket with MRK Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.